a highly sensitive troponin i assay based on a new ...plaza.umin.ac.jp/j-jabs/33/33.213.pdfunique...
TRANSCRIPT
â . ã¯ããã«
å»çãåãå·»ãç°å¢ãæ¥æ¿ã«å€åããäžãæ£è æ§ã®èŠç¹ã«åºã¥ããã質ã®é«ãããã€å¹ççãªå»çã®æäŸãæ±ããããŠããããããã®èŠç¹ããèŠããšçŸç¶ã®ã€ã ãã¢ãã»ã€æ³ã«ã¯ä»¥äžã®èª²é¡ãæããããã
1) æ£è æ§ã®èŠç¹ãå»çã®è³ªããèŠã課é¡âçååŠãè¡æ¶²åŠæ€æ»ãšæ¯èŒããŠåå¿æéãé·
ããT.A.TïŒTurn Around TimeïŒãé éãšãªããããæ£è æ§ã®åŸ ã¡æéã延é·ãããŸããèšåºããã®è³æ¥æ€æ»ã蚺çåæ€æ»ã®èŠæ±ã«å¯Ÿå¿ã§ããªãã
â誰ã§ãç°¡åã«æž¬å®ã§ããåæè£ çœ®ãè©Šè¬ããªãã枬å®ã®ããã®å°ä»»è ãå¿ èŠã«ãªãããã粟床ã®é«ãå€éæ€æ»ãç·æ¥æ€æ»ãå®æœã§ããªãã
âå€éã®æ€äœãå¿ èŠãªãããæ£è æ§ã®è² æ ã倧ããããŸããæ°çå ã§ã¯æž¬å®ãäžå¯èœãªé ç®
çç©è©ŠæåæãVol. 33, No 3 (2010)
ã·ãŒã¡ã³ã¹ãã«ã¹ã±ã¢ã»ãã€ã¢ã°ãã¹ãã£ã¯ã¹æ ªåŒäŒç€ŸããŒã±ãã£ã³ã°éšã141-8673 æ±äº¬éœåå·åºæ±äºåç°3-20-14 é«èŒªããŒã¯ã¿ã¯ãŒ
Siemens Healthcare Diagnostics K.K.,Takanawa Park Tower 3-20-14, Higashi-Gotanda,Shinagawa-ku, Tokyo 141-8673, Japan
ïŒ 213 ïŒ
æ°ããã€ã ãã¢ãã»ã€ãLOCITMæ³ããçšããé«æ床ããããã³I 枬å®
暪山ç¥åãäŒè€ä¿å¹ž
A highly sensitive Troponin I assay based on a new immunoassay 'LOCI advanced chemiluminescence'
Tomoko Yokoyama and Toshiyuki Ito
Summary LOCI⢠technology represents an important advance in immunoassay testing, enabling
unique ultra-integration with unprecedented turnaround times and sensitivity. This innovative
chemiluminescence technology provides unlimited potential for developing even the most complex
immunoassays such as highly sensitive Troponin I.
The Dimension Vista⢠500 system was designed as a consolidated middle throughput analyzer
offering a broad menu and many ease-of-use features to optimize workflow. Multiple independent
detection modules enable the processing of both routine and specialty plasma protein assays, and highly
sensitive immunoassays together with clinical chemistry assays and electrolytesâall from the same
sample tube.
Key words: Dimension Vista⢠500, High sensitivily Troponin I, LOCI⢠technology
ãç¹éïŒæ°ãããã¯ãããžãŒã»ã€ã ãã¢ãã»ã€ã
ããããå ç«è¡æž åŠæ€æ»åãã®å°çšè£ 眮ã䜿çšããããã«ãæ€äœã®å°åããå¿ èŠã«ãªããå€ãã®æ¡è¡éãå¿ èŠãšãªãã
2) å»çå¹çãçµå¶å¹çæ¹åããèŠã課é¡âå ç«è¡æž åŠæ€æ»åãã®å°çšè£ 眮ã䜿çšãããããè£ çœ®ã®åææè³ãæ¶èåè²»ãä¿å®ã»ã¡ã³ããã³ã¹è²»çšãšæéããªãã¬ãŒã·ã§ã³ã®ããã®äººä»¶è²»ããã¬ãŒãã³ã°æéãèšçœ®ã¹ããŒã¹çãå¿ èŠãšãªãã
ãããã®èª²é¡ãå æãããããæ©åšã®ã¢ãžã¥ãŒã«åãçååŠæ€æ»ãšã®çµ±åãšãã£ããæ©åšã®éçŽåãé²ããããŠããããå®éã¯è€æ°ã®è£ 眮ãçµåããŸãã¯äžäœåããã ããšãã£ãèŠãããã®çµ±åãæ£èŠãããããããã¯ãæ€äœå°åãäœæ¥ã®åæžã¯æåŸ ã§ãããã®ã®ãæ€äœãåã¢ãžã¥ãŒã«ã«ãŠé 次枬å®ããããããå ±åæéã®ççž®ã¯æåŸ ã§ãããã¢ãžã¥ãŒã«æ¯ã«æ¶èåã³ã¹ããã¡ã³ããã³ã¹ã³ã¹ãçãå¿ èŠã§ãããã³ã¹ããã¯ãŒã¯ããŒããæéãã¹ããŒã¹ã®åæžã«ãéçããããšèãããããã·ãŒã¡ã³ã¹ãã«ã¹ã±ã¢ã»ãã€ã¢ã°ãã¹ãã£ã¯ã¹ç€Ÿãéçºããããã³ããæã€LOCI TMæ³ïŒLuminescent Oxygen Channeling ImmunoassayïŒã¯ãBFåé¢ãå¿ èŠãšããªããã¢ãžãã¢ã¹ãªæž¬å®åçã§ãããç²ç¶è ºãã«ã¢ã³ãå¿çããŒã«ãŒãè «çããŒã«ãŒã貧è¡é¢é£ããŒã«ãŒãåçš®ãã«ã¢ã³ã®æž¬å®ãå¯èœã§ãããä»åã¯LOCITMæ³ãã¯ãããšããïŒã€ã®æž¬å®å
çãäžå°ã®æ©åšã«éçŽããããã£ã¡ã³ã·ã§ã³ãã¹ã¿ 500ãã®åºæ¬æ§èœãšLOCITMæ³ã®æž¬å®åçãLOCITMæ³ãçšããå枬å®é ç®ã®ãã¡ãé«æ床å¿çããããã³I 枬å®ã®æŠèŠã«ã€ããŠçŽ¹ä»ããã
â ¡. ãã£ã¡ã³ã·ã§ã³ãã¹ã¿ 500ã®æŠèŠ
ã·ãŒã¡ã³ã¹ãã«ã¹ã±ã¢ã»ãã€ã¢ã°ãã¹ãã£ã¯ã¹ç€Ÿã§ã¯2008幎ã«ïŒã€ã®åçã§ãããã©ãã¡ããªãŒæ³ãV-LYTETMé»æ¥µã»ã³ãµãŒæ³ãããã§ãã¡ããªãŒæ³ãLOCITMæ³ãéçŽããçååŠããé«æ床ã€ã ãã¢ãã»ã€ãŸã§æž¬å®ã§ããåæå€é ç®èªååæè£ çœ®ããã£ã¡ã³ã·ã§ã³ãã¹ã¿ 1500ããçºå£²ããŠãããä»åçºå£²ãããããã£ã¡ã³ã·ã§ã³ãã¹ã¿ 500ãã¯ãã£ã¡ã³ã·ã§ã³ãã¹ã¿ 1500ã®çµ±åæ©ãšããŠã®ã³ã³ã»ããããã®ãŸãŸç¶æ¿ããäžå°èŠæš¡æœèšåãã®åŠçèœåãæèŒããå ç«çååŠæž¬å®æ©ã§ããïŒå³ïŒïŒãè¡šïŒã«ç€ºãããšããããã£ã¡ã³ã·ã§ã³ãã¹ã¿
çãç©ãè©Šãæãåãæ
ïŒ 214 ïŒ
Vista® 500 ãVista® 1500
Reagent Flex/QC/Cal ã¹ãããæ° ã 144 ãã 166
ãµã³ãã«å泚ãããŒãæ° ãã 3 5
è©Šè¬å泚ãããŒãæ° ãã 3 6
ãã¥ãããæŽæµã¹ããŒã·ã§ã³æ° ãã 5 9
IMT ïŒ Photpmetry (test/hour) ã1,000 ã 2,000
LOCIæ³ (test/hour) ã 180 180
Nephelometry (test/hour) ã 150 200
åŠç
èœå
å³ïŒ ãã£ã¡ã³ã·ã§ã³ãã¹ã¿ 500å€èŠ³
è¡šïŒ ãã£ã¡ã³ã·ã§ã³ãã¹ã¿ 500ãšãã¹ã¿ 1500ã®æ¯èŒ
500ãšãã¹ã¿ 1500ã®äž»ãªéãã¯åŠçèœåã§ããããã©ãã¡ããªãŒæ³ã§ã¯å€§ããåŠçèœåãç°ãªããããããLOCITMæ³ã®åŠçèœåã¯å ±éã§ãããããã§ãã¡ããªãŒæ³ã§ã倧ããªæžå°ã¯ãªãããã®ããšã¯ãæœèšã§ã®æž¬å®é ç®ã«å¿ããæ©çš®ã®éžæã®å¹ ãåºãããã客æ§ã®ããŒãºã«å¿ããææ¡ãå¯èœã«ãªããšèããããããã£ã¡ã³ã·ã§ã³ãã¹ã¿ 500ã¯ã¯ãŒã¯ã»ã«æ¹åŒãæ¡çšããŠãããè€æ°ã®åæè£ çœ®ããã åã«çµåããåŸæ¥ã®ã¢ãžã¥ã©ãŒæ¹åŒãšã¯ç°ãªããå šãŠã®é ç®ãïŒå°ã®åæè£ çœ®ã§åæã«æž¬å®å¯èœã§ãããïŒæ¬ã®æ¡è¡ç®¡ãåæè£ çœ®ã移åããŠæž¬å®ãã¹ã¿ãŒãããã¢ãžã¥ã©ãŒæ¹åŒãšã¯ç°ãªããïŒå°ã®åæè£ çœ®ããããïŒæ¬ã®æ€äœãããå šãŠã®é ç®ãåæã«æž¬å®ããããšã«ãããçååŠããé«æ床ã€ã ãã¢ãã»ã€ãŸã§å šãŠã®æž¬å®çµæãã»ãŒåæã«ã¿ã€ã ãªãŒã«å ±åå¯èœã§ããããŸããåæè£ çœ®ã®å°æ°ãå€§å¹ ã«åæžããããšã«ãããã¡ã³ããã³ã¹ããã£ãªãã¬ãŒã·ã§ã³ãè©Šè¬è£å ãš
ãã£ãæ¥åãå€§å¹ ã«å¹çåã§ããããã«ãã¹ããŒã¹ãæ¶èåãåææè³ãšãã£ãã³ã¹ããåæžãæåŸ ã§ããããã£ã¡ã³ã·ã§ã³ ãã¹ã¿ 500ã¯åæã«144æ¬ã®
è©Šè¬ã«ãŒããªããžããŸãã¯QC/ãã£ãªãã¬ãŒã¿ãã€ã¢ã«ã©ãã¯ã®æèŒãå¯èœã§ããïŒå³ïŒïŒããŸãã枬å®å¯èœé ç®ã«é¢ããŠãå³ïŒã«ç€ºãããšããã100é ç®ä»¥äžã®è©Šè¬ãæ¢ã«çºå£²æžã¿ã§ããïŒå³ïŒïŒã
â ¢. LOCITMæ³ã®æž¬å®åç
LOCITMïŒLuminescent Oxygen ChannelingImmunoassayïŒæ³ã¯ãäžéé é žçŽ ãããªã¬ãŒãšããBFåé¢ã®å¿ èŠã®ãªããã¢ãžãã¢ã¹ãªã€ã ãã¢ãã»ã€ã§ãããLOCITMæ³ã«ã¯ïŒçš®é¡ã®ããªã¹ãã¬ã³ç²åãã»ã³ã·ããŒãºãšã±ãããŒãºã䜿çšãããã»ã³ã·ããŒãºã¯çŽåŸ200 nmã®ããªã¹ãã¬ã³ç²åã§ããã
çç©è©ŠæåæãVol. 33, No 3 (2010)
ïŒ 215 ïŒ
å³ïŒ è©Šè¬ã«ãŒããªããž/ãã€ã¢ã«ã©ãã¯è£ å¡«ããžã·ã§ã³
å³ïŒ 枬å®é ç®
ãã¿ãã·ã¢ãã³ãšããéè²ã®è²çŽ ãå«ãã§ããïŒå³ïŒïŒããã¿ãã·ã¢ãã³ã¯ã680 nmã®å ãåžåããå±èµ·ç¶æ ããåºåºç¶æ ã«æ»ãéã«äžéé é žçŽ ãçºçãããäžéé é žçŽ ã«ã¯é»åã空ã®è»éãååšãã匷åãªé žåäœçšããã€ïŒå³ïŒïŒãäžéé é žçŽ ã®åæžæã¯ïŒÎŒç§ã§ãããäžç¬ã«ããŠéåžžã®é žçŽ ã®é»åé åã«æ»ããåŸã£ãŠãæ¥è¿ããŠããç©è³ªã«å¯ŸããŠã®ã¿äžéé é žçŽ ã®é žåäœçš
ãçºæ®ããããã»ã³ã·ããŒãºã®è¡šé¢ã«ã¯ã¹ãã¬ããã¢ããžã³ãçµåããŠãããããªãã³åæäœãšåå¿ãããã±ãããŒãºã¯çŽåŸ200 nmã®ããªã¹ãã¬ã³ç²åã§ãããè¡šé¢ã«ã¯æž¬å®ç©è³ªãšåå¿ããç¹ç°æäœãçµåããŠããããªã¬ãã£ã³ååç©ãšãŠãŠãããŠã é¯äœãå«ãŸããŠããïŒå³ïŒïŒããªã¬ãã£ã³ååç©ã¯äžéé é žçŽ ã«ããé žåããçºå ããããŸãããŠãŠãããŠã é¯äœã¯ãªã¬ãã£ã³ååç©ã®çºå ãšãã«ã®ãŒãåžåã612 nmã®å ãçºå ãããæ€äœäžã®ç®çç©è³ªã¯ããªãã³åæäœãšåå¿ããã±ãããŒãºäžã®æäœãšåå¿ãããããã«ãã¹ãã¬ããã¢ããžã³çµåã»ã³ã·ããŒãºãšåå¿ããã»ã³ã·ããŒãº-ç®çç©è³ª-ã±ãããŒãºè€åäœã圢æããã»ã³ã·ããŒãºãšã±ãããŒãºãæ¥è¿ããïŒå³ïŒïŒãïŒã€ã®ããŒãºãæ¥è¿ããç¶æ ã§680 nmã®å ãã»ã³ã·ããŒãºã«ç §å°ãããšãäžéé é žçŽ ãçºçããã±ãããŒãºãšåå¿ã612 nmã®å ãçºå ããïŒå³ïŒïŒãäžæ¹ãæ€äœäžã«ç®çç©è³ªãååšããªãå Žåãè€åäœã圢æãããïŒã€ã®ããŒãºãé¢ããç¶æ ã§ååšãããïŒã€ã®ããŒãºãé¢ããç¶æ ã§680 nmã®å ãç §å°ãããšäžéé é žçŽ ã¯çºçãããåæžæãïŒÎŒç§ãšçãã±ãããŒãºãšã¯åå¿ããªãããçºå ããªããæ€äœäžã®ç®çç©è³ªãå€ãã»ã©ãããå€ãã®è€åäœã圢æããã
çãç©ãè©Šãæãåãæ
ïŒ 216 ïŒ
å³ïŒ ã»ã³ã·ããŒãº
å³ïŒ é žçŽ ååãšäžéé é žçŽ ã®é»åé 眮
å³ïŒ ã±ãããŒãº
å³ïŒ è€åäœã®åœ¢æ
å³ïŒ è€åäœã«ããçºå åç
ã»ã³ã·ããŒãºãšã±ãããŒãºãæ¥è¿ããããšã«ããçºå éãå¢å ããã612 nmã®å ã®åŒ·åºŠããæ¢ç¥æ¿åºŠã®æšæºæ¶²ã®å ã®åŒ·ããšæ¯èŒããæ€äœäžã®ç®çç©è³ªã®æ¿åºŠãç®åºãããLOCITMæ³ã§ã¯ãå ã®ç §å°ãçºå ã枬å ãç¹°ãè¿ãå®æœããããšã«ããããã倧ããªã·ã°ãã«ãåŸãããå¶çºçã«çºçãããã€ãºãåžåããããšãã§ããã
â £. LOCIæ³ã«ããå¿çããããã³Iã®æž¬å®åç
ããã¬ãã¯ã¹ã«ãŒããªããž ããããã³I VãïŒãã£ã¡ã³ã·ã§ã³ãã¹ã¿çšå¿çããããã³I枬å®è©Šè¬ïŒã¯ãã¢ãžãã¢ã¹ãµã³ãã€ããååŠçºå å ç«æž¬å®æ³ã«ããè¡æž ãŸãã¯è¡æŒ¿äžã®å¿çããããã³Iã枬å®ããè©Šè¬ã§ãããæ¬è©Šè¬ã«ã¯ãïŒã€ã®åæç²åè©Šè¬ãšããªãã³åæå¿çããããã³IããŠã¹ã¢ãã¯ããŒãã«æäœãã©ã°ã¡ã³ããå«ãŸãããïŒã€ç®ã®ç²åè©Šè¬ïŒã¹ãã¬ããã¢ããžã³åžçãã¿ãã·ã¢ãã³å«æããªã¹ãã¬ã³ç²åã以äžãã»ã³ã·ããŒãºïŒã¯ã¹ãã¬ããã¢ããžã³ã§ã³ãŒãã£ã³ã°ãããæå è²çŽ ãå«æãããïŒã€ç®ã®ç²åè©Šè¬ïŒæå¿çããããã³IããŠã¹ã¢ãã¯ããŒãã«æäœåžçãªã¬ãã£ã³ããŠãŠãããŠã é¯äœå«æããªã¹ãã¬ã³ç²åã以äžãã±ãããŒãºïŒã¯ãå¥ã®æå¿çããããã³IããŠã¹ã¢ãã¯ããŒãã«æäœã§ã³ãŒãã£ã³ã°ãããååŠçºå è²çŽ ãå«æããã枬å®è©Šæã¯ãã±ãããŒãºãšããªãã³åæäœãšå ±ã«ã€ã³ãã¥ããŒã·ã§ã³ãããç²åïŒå¿çããããã³IïŒããªãã³åæäœã®å ç«è€åäœã圢æãããã»ã³ã·ããŒãºãæ·»å ãããŠããªãã³ãšçµåããïŒã€ã®ããŒãºã«ããå ç«è€åäœã圢æãããè€åäœã«680 nmã®å ãç §å°ãããšãã»ã³ã·ããŒãºããäžéé é žçŽ ãçºçããã±ãããŒãºãž
ãšæ¡æ£ãååŠçºå ãçãããã·ã°ãã«ã¯612 nmã§æž¬å®ããã枬å®è©Šæäžã®çºå éããå¿çããããã³Iæ¿åºŠãç®åºããã
â €. LOCIæ³ã«ããå¿çããããã³Iã®åºç€æ§èœ
è¡šïŒã«ç€ºãããšããããã£ã¡ã³ã·ã§ã³ãã¹ã¿çšããã¬ãã¯ã¹ã«ãŒããªããž ããããã³I Vãã¯å°ãªãæ€äœéã«ãŠãé«æ床ãçæé枬å®ãå¯èœã§ããã
1) åæåçŸæ§ïŒçš®é¡ã®ããŒã«è¡æž ã20å枬å®ãåçŸæ§ãæ±ããã1.9ïœ9.0ïŒ ã®è¯å¥œãªåçŸæ§ã確èªãããïŒè¡šïŒïŒã
2) å®å¹æ床æ£è æ€äœã20é枬å®ãå¹³åå€ãšCVïŒ ãæ±ãã°ã©ãã«ãããããããCVïŒ ã10ïŒ ã瀺ãæ¿åºŠãã°ã©ãããæ±ãå®å¹æ床ãšãããå®å¹æ床ã¯0.04 ng/mLã§ãã£ãïŒå³ïŒïŒã
3) çžé¢æ§åçµä¿åãããæ£è æ€äœ50æ€äœããã£ã¡ã³ã·ã§ã³çšããã¬ãã¯ã¹ã«ãŒããªããž ããããã³ïŒ©ã ãªãã³ã«ããã£ã¡ã³ã·ã§ã³ ãã¹ã¿çšããã¬ãã¯ã¹ã«ãŒããªããž ããããã³I VããçšããŠæž¬å®ãããå³10ã«ç€ºãããšãããè¯å¥œãªçžé¢æ§ïŒYïŒ0.96XïŒ0.12ãr = 0.97ïŒã確èªãããïŒå³10ïŒã
4) åºæºç¯å²å¥åžžè 199åã®è¡æž æ€äœãçšããŠå®æœããè©ŠéšçµæãããåŸãããåºæºç¯å²ïŒ99ããŒã»ã³ã¿ã€ã«å€ïŒã¯ã0.045 ng/mLã§ãã£ãïŒå³11ïŒã
çç©è©ŠæåæãVol. 33, No 3 (2010)
ïŒ 217 ïŒ
Assey Time: 10 min
Assey Range: 0.005-50 ng/mL
Analytical Sensitivity: 0.005 ng/mL
Sample Volume: 20 ÎŒL
Specimen Types: serum
heparin plasma
Sample Mean Within-Run (%CV)
Pool 1 0.02 ng/mL 9.0ãããããã
Pool 2ããã 0.06 ng/mL 4.7
Pool 3ããã 0.33 ng/mL 2.6
Pool 4ããã 2.26 ng/mL 1.9
Pool 5ããã 29.7 ng/mL 2.4ãããã
è¡šïŒ ãã¬ãã¯ã¹ã«ãŒããªããžããããã³ïŒ©V åºæ¬æ§èœ
è¡šïŒ åæåçŸæ§
â ¥. é«æ床å¿çããããã³æž¬å®ã®
èšåºçæçšæ§ãšä»åŸã®å±æ
è¡äžå¿çããããã³æž¬å®ç³»ã¯éªšæ Œçã®ããããã³ãšäº€å·®ãããå¿çç¹ç°çã§ããããšããã2000幎ã®ã欧å·å¿èç åŠäŒ/ç±³åœå¿èç åŠäŒïŒESC/ACCïŒæ¥æ§å¿çæ¢å¡èšºæã¬ã€ãã©ã€ã³ã®æ¹å®ãããæ¥æ§å¿çæ¢å¡èšºæã«ãããçååŠããŒã«ãŒã®ç¬¬äžéžæãšãããããã«ãªã£ã1)ããŸã2007幎ã«ã¯ã欧å·å¿èç åŠäŒ/ç±³åœå¿èç åŠäŒ/ç±³åœå¿èåäŒ/äžçå¿èé£åïŒESC, ACC, AHA,WHFïŒã«ããã³ã³ã»ã³ãµã¹ã®åããæ¥æ§å¿çæ¢å¡èšºæã¬ã€ãã©ã€ã³ã®åæ¹å®ããçºè¡šãããå¿çããããã³ã®èšºæåºæºå€ã§ãããå¥åžžè ã®99ããŒã»ã³ã¿ã€ã«å€ã«ãããå€åä¿æ°ïŒCVïŒïŒ ã10ïŒ ä»¥äžã§ããé«æ床詊è¬ããæšå¥šãããŠãã2), 3)ããããåããŠè¿å¹Žã§ã¯ããããã³è©Šè¬ã®é«æ床åãé²ã¿ã€ã€ããããçŸåšãŸã§ã®ãšã
ãé«æ床ããããã³è©Šè¬ã«è©²åœãããã®ã¯ãŸã å°ãªããããã¬ãã¯ã¹ã«ãŒããªããžããããã³IVãã¯ãããæºããé«æ床å¿çããããã³æž¬å®è©Šè¬ã®ïŒã€ã§ãã4)ãåŸæ¥æ³ã§ã¯å¿çæ¢å¡çºçïŒãïŒæé以å ã®è¶ æ¥æ§æã®æ€æ»ã«å¿çããããã³ã¯äžåããšãããããªã°ããã³ãH-FABPãªã©ã§è©äŸ¡ããŠããããé«æ床枬å®ã®å®çŸã«ãããå¿çããããã³æž¬å®ã®å¿çæ¢å¡è¶ æ¥æ§æ蚺æããªã¹ã¯è©äŸ¡ã«ãããæçšæ§ã瀺åãããŠãã1)ããŸããå¿äžå šã®æ²»çã»åå 究æã»ãªã¹ã¯è©äŸ¡ã«ã€ããŠããé«æ床å¿çããããã³æž¬å®ãçšããŠåŸæ¥æ³ã§ã¯å°é£ã§ãã£ãå¥åžžäººã®99ããŒã»ã³ã¿ã€ã«å€ã«è¿ãäœå€é åã粟床ãã枬å®ããããšã§ãä»åŸãã詳现ãªè§£æãé²ã¿ãå°æ¥ã¯å¿äžå šã®äžè¬æ€æ»ãšãªãå¯èœæ§ãé«ããšèããããŠãã1)ãä»åŸã®å±æãšããŠã¯ãæœåšæ§åŸ®å°å¿çé害ã®æ€åºãç®çã«æ€èšºãã¯ãããšããäžè¬äœæ°ãžã®å¿çšãé«è¡å§æ£è ãžã®å¿çšãæåŸ ãããŠããã
ãåèæç®ãïŒ) äœè€å¹žäºº: è¡äžå¿çããããã³æž¬å®. æ€æ»ãšæè¡,36: 754-762, 2008.
ïŒ) Thygesen K, Alpert JS, White HD, et al.: Universaldefinition of myocardial infection. Circulation, 116:2634-2653, 2007.
ïŒ) Thygesen K, Alpert JS, White HD, et al.: Universaldefinition of myocardial infection. Euro Heart J 28:2525-2538, 2008.
ïŒ) http://www.ifcc.org/PDF/ScientificActivities/Committees/C-SMCD/cTn_Assay_Table_v091209.pdf
çãç©ãè©Šãæãåãæ
ïŒ 218 ïŒ
å³ïŒ å®å¹æ床
å³10 çžé¢
å³11 åºæºç¯å²